Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 7/20 | 0.69 |
| ▸ | CDC25B | P30305 | 7/20 | 0.69 |
| ▸ | CDC25C | P30307 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6243699 | 0.98 | CDC25A (0.72) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL9631357 | 0.98 | CDC25A (0.72) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL6242255 | 0.98 | CDC25A (0.72) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL17706772 | 0.98 | CDC25A (0.72) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL11176370 | 0.98 | CDC25A (0.72) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL27810681 | 0.98 | CDC25A (0.72) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL17122005 | 0.93 | CDC25A (0.68) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL4302635 | 0.92 | CDC25A (0.60) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL23581852 | 0.87 | CDC25A (0.56) | CDC25ACDC25BCDC25CALDH1A1MAPT | |
| SCHEMBL2662258 | 0.86 | CDC25A (0.55) | CDC25ACDC25BCDC25CALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991012139-A1 | IMAGING PROCESS | COURTAULDS PLC (GB) | 1991-08-22 | — | — | WO | claimed |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7982048-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982048-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-20060069259-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2006-03-30 | — | — | US | disclosed |
| US-20050096279-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6855826-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040110692-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-6664420-B2 | For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia | MAGNESIUM DIAGNOSTICS, INC. | 2003-12-16 | — | — | US | disclosed |
| EP-1355638-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | Magnesium Diagnostics, Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030040625-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6455734-B1 | ADMINISTERING PHENYLGLYCINAMIDE(N-2,4-DIAMYLPENTANOIC ACID AMIDE) AS HYPOTENSIVE AGENTS FOR PROPHYLAXIS OF INSULIN RESISTANCE, ECLAMPSIA AND SENSITIVITY TO BLOOD METAL CONCENTRATIONS | MAGNESIUM DIAGNOSTICS, INC. | 2002-09-24 | — | — | US | disclosed |
| WO-2002011714-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-1991012139-A1 | IMAGING PROCESS | COURTAULDS PLC (GB) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110692-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | CDC25A 2009/4885CDC25B 2269/4885CDC25C 2669/4885 |
| US-20030040625-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | ECE1, PLPBP, ECE2 | CDC25A 1713/4885CDC25B 1914/4885CDC25C 2385/4885 |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | CDC25A 2009/4885CDC25B 2269/4885CDC25C 2669/4885 |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | CDC25A 2009/4885CDC25B 2269/4885CDC25C 2669/4885 |
| US-20060069259-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | ECE1, PLPBP, ECE2 | CDC25A 1713/4885CDC25B 1914/4885CDC25C 2385/4885 |
| US-20050096279-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | CDC25A 2009/4885CDC25B 2269/4885CDC25C 2669/4885 |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | PLPBP, ECE1, MCU | CDC25A 2009/4885CDC25B 2269/4885CDC25C 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.